Announced
Financials
Tags
life sciences
Private Equity
Private
Domestic
United States
Majority
Biotechnology
Friendly
therapeutics
Acquisition
Single Bidder
Pending
Synopsis
Amgen, a biotechnology firm, agreed to acquire Rodeo Therapeutics, a developer of small-molecule therapies, from Accelerator Life Science Partners, a venture capital firm, for c.$720m. "With decades of experience in developing, manufacturing and commercializing innovative therapies for patients suffering from a broad range of immunologic diseases and conditions, Amgen is ideally positioned to rapidly advance our program into the clinic," Thong Q. Le, Rodeo President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.